Citigroup Inc Oncorus, Inc. Transaction History

Citigroup Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	BUY	$0.24 - $0.76 $3 - $11	15 Added 3.05%	506 $0
Q3 2022 Nov 10, 2022	SELL	$0.85 - $1.65 $1,389 - $2,697	-1,635 Reduced 76.9%	491 $0
Q2 2022 Aug 10, 2022	BUY	$1.04 - $1.86 $719 - $1,287	692 Added 48.26%	2,126 $3,000
Q1 2022 May 12, 2022	SELL	$1.44 - $5.62 $6,373 - $24,874	-4,426 Reduced 75.53%	1,434 $3,000
Q4 2021 Feb 10, 2022	BUY	$5.03 - $11.63 $17,760 - $41,065	3,531 Added 151.61%	5,860 $31,000
Q3 2021 Nov 10, 2021	BUY	$9.29 - $14.27 $21,636 - $33,234	2,329 New	2,329 $22,000

Ticker ONCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,973,100
Description
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various canc...

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

Stay updated on Citigroup Inc with notifications on news.